Schrödinger Valuation

Is SDGR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SDGR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SDGR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SDGR's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SDGR?

Other financial metrics that can be useful for relative valuation.

SDGR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.2x
Enterprise Value/EBITDA-6.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SDGR's PS Ratio compare to its peers?

The above table shows the PS ratio for SDGR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.8x
TDOC Teladoc Health
0.5x0.8%US$1.3b
PHR Phreesia
3.5x12.1%US$1.4b
NXGN NextGen Healthcare
2.3x6.7%US$1.6b
CERT Certara
5x9.8%US$1.8b
SDGR Schrödinger
7.4x17.3%US$1.5b

Price-To-Sales vs Peers: SDGR is expensive based on its Price-To-Sales Ratio (7.4x) compared to the peer average (3x).


Price to Earnings Ratio vs Industry

How does SDGR's PE Ratio compare vs other companies in the US Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.9%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.9%
n/an/an/a
No more companies

Price-To-Sales vs Industry: SDGR is expensive based on its Price-To-Sales Ratio (7.4x) compared to the US Healthcare Services industry average (1.9x).


Price to Sales Ratio vs Fair Ratio

What is SDGR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SDGR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.4x
Fair PS Ratio3.9x

Price-To-Sales vs Fair Ratio: SDGR is expensive based on its Price-To-Sales Ratio (7.4x) compared to the estimated Fair Price-To-Sales Ratio (3.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SDGR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$20.50
US$33.27
+62.3%
20.9%US$50.00US$25.00n/a11
Sep ’25US$21.03
US$33.27
+58.2%
20.9%US$50.00US$25.00n/a11
Aug ’25US$22.60
US$34.27
+51.6%
22.2%US$50.00US$25.00n/a11
Jul ’25US$18.76
US$36.50
+94.6%
19.5%US$50.00US$25.00n/a10
Jun ’25US$21.52
US$36.50
+69.6%
19.5%US$50.00US$25.00n/a10
May ’25US$25.26
US$37.70
+49.2%
17.2%US$50.00US$26.00n/a10
Apr ’25US$26.33
US$37.70
+43.2%
17.2%US$50.00US$26.00n/a10
Mar ’25US$26.81
US$37.70
+40.6%
17.2%US$50.00US$26.00n/a10
Feb ’25US$26.63
US$42.20
+58.5%
20.3%US$60.00US$29.00n/a10
Jan ’25US$35.80
US$44.22
+23.5%
19.3%US$60.00US$29.00n/a9
Dec ’24US$32.49
US$48.22
+48.4%
29.8%US$80.00US$29.00n/a9
Nov ’24US$21.82
US$53.44
+145.0%
24.8%US$80.00US$31.00n/a9
Oct ’24US$28.27
US$56.44
+99.7%
22.8%US$80.00US$31.00n/a9
Sep ’24US$36.71
US$56.44
+53.8%
22.8%US$80.00US$31.00US$21.039
Aug ’24US$52.33
US$58.56
+11.9%
28.6%US$86.00US$23.00US$22.609
Jul ’24US$49.92
US$55.56
+11.3%
33.9%US$86.00US$23.00US$18.769
Jun ’24US$35.09
US$51.78
+47.6%
38.5%US$86.00US$23.00US$21.529
May ’24US$30.88
US$51.25
+66.0%
40.4%US$86.00US$24.00US$25.268
Apr ’24US$26.33
US$51.38
+95.1%
40.0%US$86.00US$25.00US$26.338
Mar ’24US$24.60
US$55.33
+124.9%
41.2%US$89.00US$25.00US$26.819
Feb ’24US$25.14
US$55.44
+120.5%
42.2%US$87.00US$23.00US$26.639
Jan ’24US$18.69
US$55.67
+197.8%
40.8%US$86.00US$23.00US$35.809
Dec ’23US$17.63
US$61.00
+246.0%
32.4%US$86.00US$37.00US$32.498
Nov ’23US$24.69
US$65.63
+165.8%
31.9%US$89.00US$38.00US$21.828
Oct ’23US$24.98
US$65.63
+162.7%
31.9%US$89.00US$38.00US$28.278
Sep ’23US$27.58
US$64.88
+135.2%
33.8%US$89.00US$33.00US$36.718

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies